Hereditary Cancer Testing Market Size to Reach $10.1 billion by 2031 | 11.6% CAGR

The global Hereditary cancer testing industry was estimated at $3.5 billion in 2021, and is anticipated to hit $10.1 billion by 2031, registering a CAGR of 11.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.

The hereditary cancer testing market refers to the market for genetic tests that identify inherited gene mutations associated with an increased risk of developing certain types of cancer. These tests are designed to detect specific gene mutations that are known to be linked to an elevated risk of developing cancer, such as breast cancer, ovarian cancer, colorectal cancer, or pancreatic cancer.

Hereditary cancer testing plays a crucial role in identifying individuals who have an increased risk of developing certain types of cancer due to inherited genetic mutations. It helps in identifying individuals who may benefit from early detection, surveillance, or targeted preventive measures to reduce their cancer risk.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/11503

𝐃𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐧𝐭𝐬 𝐨𝐟 𝐠𝐫𝐨𝐰𝐭𝐡-

Increase in the geriatric population, surge in incidence of cancer across the world, and rise in government expenditure on healthcare drive the growth of the global hereditary cancer testing market. On the other hand, lack of skilled professionals and high cost of the tests impede the growth to some extent. However, lucrative growth potential in untapped emerging economies is expected to create lucrative opportunities in the industry.

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐨𝐧 𝐇𝐞𝐫𝐞𝐝𝐢𝐭𝐚𝐫𝐲 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲?

The outbreak of the pandemic gave way to the closure of non-emergency departments in hospitals. Medical procedures with high priority were only being performed in the medical centers, which impacted the global hereditary cancer testing market negatively, especially during the initial period.

However, as the global situation started getting normal, the market for hereditary cancer testing also started getting back to shape.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟎𝟎 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬)@ https://www.alliedmarketresearch.com/checkout-final/7b167a99500b5b26da724d031538028d

𝐓𝐡𝐞 𝐜𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐜𝐢𝐭𝐞 𝐭𝐡𝐞 𝐟𝐚𝐬𝐭𝐞𝐬𝐭 𝐂𝐀𝐆𝐑-

By cancer type, the other cancers segment contributed to nearly two-thirds of the global hereditary cancer testing market share in 2021, and is expected to lead the trail by 2031. This is attributed to increase in the prevalence of breast cancer and rise in the geriatric population as they are more prone to chronic diseases. The colorectal cancer segment, however, is expected to exhibit the fastest CAGR of 13.4% from 2022 to 2031. This is due to surge in the number of breast cancer patients and increase in the number of cancer testing products available in the market.

𝐓𝐡𝐞 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐯𝐞 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐝𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐛𝐲 𝟐𝟎𝟑𝟏-

By test type, the predictive testing segment garnered more than two-thirds of the global hereditary cancer testing market share in 2021, and is expected to retain its dominance by 2031. The same segment would also portray the fastest CAGR of 11.9% during the forecast period. This is due to upsurge in demand for predictive testing performed in the hospitals and rise in the preference for predictive testing.

𝐓𝐡𝐞 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐠𝐚𝐫𝐧𝐞𝐫𝐞𝐝 𝐭𝐡𝐞 𝐦𝐚𝐣𝐨𝐫 𝐬𝐡𝐚𝐫𝐞 𝐢𝐧 𝟐𝟎𝟐𝟏-

By end user, the hospitals segment garnered nearly half of the global hereditary cancer testing market share in 2021, and is expected to retain its dominance by 2031. This is due to increase in the number of hospitals, surge in healthcare expenditure, and rise in the hospital visits of cancer patients for early diagnosis of cancers. The diagnostic centers segment, on the other hand, is expected to exhibit the fastest CAGR of 12.2% from 2022 to 2031, due to rise in the number of diagnostic centers and increase in adoption of hereditary cancer testing in the diagnostic centers.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/11503

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐠𝐫𝐚𝐛𝐛𝐞𝐝 𝐭𝐡𝐞 𝐡𝐢𝐠𝐡𝐞𝐬𝐭 𝐬𝐡𝐚𝐫𝐞-

Based on region, North America held the major share in 2021, generating nearly two-fifths of the global hereditary cancer testing market. This is due to rise in the geriatric populatio, and surge in number of diagnostic procedures in the province. The Asia-Pacific region, however, would cite the fastest CAGR of 13.8% throughout the forecast period. This is due to the increasing prevalence of cancer types and the rising number of product launch & product approvals across the region.

𝐇𝐞𝐫𝐞𝐝𝐢𝐭𝐚𝐫𝐲 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐊𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬:

Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Abbott Laboratories
Eurofins Scientific SE
Illumina, Inc.
Myriad Genetics, Inc.
Qiagen N.V.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche AG

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

X-Ray Detector Market: https://www.alliedmarketresearch.com/x-ray-detectors-market

Drug Discovery Informatics Market: https://www.alliedmarketresearch.com/drug-discovery-informatics-market-A07074

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐮𝐬:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.